Why GLP-3-R is one of the most-watched research peptides of the decade
The 2023 NEJM publication describing the Phase 2 Retatrutide trial drew significant attention from the metabolic-research community for the triple-agonist mechanism's reported effects. GLP-3-R is BioInfinity Lab's research-grade analog of that compound, intended exclusively for laboratory research replicating or extending the cited literature.